TIGIT inhibitory checkpoint molecule competes with activating DNAM1 receptor for the same ligands on tumor cells and in CRC patients it is more highly expressed on intratumoral NK cells than on peritumoral NK cells (Zhang et al., 2018). This evidence concerns the gene TIGIT and neoplasm.